These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. O Schoenfeld JD; Sibenaller ZA; Mapuskar KA; Wagner BA; Cramer-Morales KL; Furqan M; Sandhu S; Carlisle TL; Smith MC; Abu Hejleh T; Berg DJ; Zhang J; Keech J; Parekh KR; Bhatia S; Monga V; Bodeker KL; Ahmann L; Vollstedt S; Brown H; Shanahan Kauffman EP; Schall ME; Hohl RJ; Clamon GH; Greenlee JD; Howard MA; Schultz MK; Smith BJ; Riley DP; Domann FE; Cullen JJ; Buettner GR; Buatti JM; Spitz DR; Allen BG Cancer Cell; 2017 Apr; 31(4):487-500.e8. PubMed ID: 28366679 [TBL] [Abstract][Full Text] [Related]
4. Role of labile iron in the toxicity of pharmacological ascorbate. Du J; Wagner BA; Buettner GR; Cullen JJ Free Radic Biol Med; 2015 Jul; 84():289-295. PubMed ID: 25857216 [TBL] [Abstract][Full Text] [Related]
9. Augmentation of intracellular iron using iron sucrose enhances the toxicity of pharmacological ascorbate in colon cancer cells. Brandt KE; Falls KC; Schoenfeld JD; Rodman SN; Gu Z; Zhan F; Cullen JJ; Wagner BA; Buettner GR; Allen BG; Berg DJ; Spitz DR; Fath MA Redox Biol; 2018 Apr; 14():82-87. PubMed ID: 28886484 [TBL] [Abstract][Full Text] [Related]
10. Enhancement of tumor radioresponse in vivo by gemcitabine. Milas L; Fujii T; Hunter N; Elshaikh M; Mason K; Plunkett W; Ang KK; Hittelman W Cancer Res; 1999 Jan; 59(1):107-14. PubMed ID: 9892194 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological Ascorbate as a Means of Sensitizing Cancer Cells to Radio-Chemotherapy While Protecting Normal Tissue. Schoenfeld JD; Alexander MS; Waldron TJ; Sibenaller ZA; Spitz DR; Buettner GR; Allen BG; Cullen JJ Semin Radiat Oncol; 2019 Jan; 29(1):25-32. PubMed ID: 30573181 [TBL] [Abstract][Full Text] [Related]
12. Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study. Martin-Liberal J; López-Pousa A; Martínez-Trufero J; Martín-Broto J; Cubedo R; Lavernia J; Redondo A; López-Martín JA; Mulet-Margalef N; Sanjuan X; Tirado ÒM; Garcia-Del-Muro X Target Oncol; 2018 Feb; 13(1):81-87. PubMed ID: 29177953 [TBL] [Abstract][Full Text] [Related]
13. Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG). Kasper B; Reichardt P; Pink D; Sommer M; Mathew M; Rauch G; Hohenberger P Mar Drugs; 2015 Jan; 13(1):379-88. PubMed ID: 25591040 [TBL] [Abstract][Full Text] [Related]
14. Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancreatic Cancer. Alexander MS; Wilkes JG; Schroeder SR; Buettner GR; Wagner BA; Du J; Gibson-Corley K; O'Leary BR; Spitz DR; Buatti JM; Berg DJ; Bodeker KL; Vollstedt S; Brown HA; Allen BG; Cullen JJ Cancer Res; 2018 Dec; 78(24):6838-6851. PubMed ID: 30254147 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue. Cojocaru E; Thway K; Fisher C; Messiou C; Zaidi S; Miah AB; Benson C; Gennatas S; Huang P; Jones RL Anticancer Res; 2020 Dec; 40(12):7003-7007. PubMed ID: 33288595 [TBL] [Abstract][Full Text] [Related]
17. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Merimsky O; Meller I; Flusser G; Kollender Y; Issakov J; Weil-Ben-Arush M; Fenig E; Neuman G; Sapir D; Ariad S; Inbar M Cancer Chemother Pharmacol; 2000; 45(2):177-81. PubMed ID: 10663634 [TBL] [Abstract][Full Text] [Related]
18. Maximizing therapeutic gain with gemcitabine and fractionated radiation. Mason KA; Milas L; Hunter NR; Elshaikh M; Buchmiller L; Kishi K; Hittelman K; Ang KK Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1125-35. PubMed ID: 10421547 [TBL] [Abstract][Full Text] [Related]
19. Phase II trial of gemcitabine in advanced sarcomas. Okuno S; Edmonson J; Mahoney M; Buckner JC; Frytak S; Galanis E Cancer; 2002 Jun; 94(12):3225-9. PubMed ID: 12115355 [TBL] [Abstract][Full Text] [Related]
20. Significant increase in residual DNA damage as a possible mechanism of radiosensitization by gemcitabine. Weiss C; Grabenbauer GG; Sauer R; Distel L Strahlenther Onkol; 2003 Feb; 179(2):93-8. PubMed ID: 12590319 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]